LUNG - Pulmonx Corporation

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, October 27, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Oct 13, 2026 12:05 PM • globenewswire.com

Owlet (NYSE:OWLT) and Pulmonx (NASDAQ:LUNG) Financial Review

Pulmonx (NASDAQ: LUNG - Get Free Report) and Owlet (NYSE: OWLT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations. Institutional and Insider Ownership 91.0% of Pulmonx shares are

Oct 05, 2026 04:14 AM • defenseworld.net

Deutsche Bank AG Takes Position in Pulmonx Corporation $LUNG

Deutsche Bank AG purchased a new stake in Pulmonx Corporation (NASDAQ: LUNG) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 402,316 shares of the company's stock, valued at approximately $523,000. Deutsche Bank AG owned approximately 0.94% of

Sep 01, 2026 11:52 PM • defenseworld.net

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.

Sep 01, 2026 12:05 PM • globenewswire.com

Pulmonx to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:

Aug 27, 2026 12:05 PM • globenewswire.com

Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Aug 26, 2026 06:55 AM • zacks.com

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year

Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.

Aug 14, 2026 10:02 PM • marketbeat.com

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Aug 14, 2026 09:01 AM • zacks.com

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aug 03, 2026 09:01 AM • zacks.com

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Jul 29, 2026 10:43 PM • seekingalpha.com

Pulmonx Q2 Earnings Call Highlights

Pulmonx NASDAQ: LUNG reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China.

Jul 29, 2026 03:04 PM • marketbeat.com

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.38 per share a year ago.

Jul 29, 2026 02:26 PM • zacks.com

Pulmonx Reports Second Quarter 2026 Financial Results

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.

Jul 29, 2026 12:05 PM • globenewswire.com

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.

Jul 28, 2026 12:05 PM • globenewswire.com

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Jul 15, 2026 12:05 PM • globenewswire.com

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

REDWOOD CITY, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026.

Jul 15, 2026 12:05 PM • globenewswire.com

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. , June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the "Grant Date"), Pulmonx granted equity awards under its 2025 Inducement Plan (the "Inducement Plan") to 17 individuals hired by Pulmonx in the first two quarters of 2026.

Jun 01, 2026 12:05 PM • globenewswire.com

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to 17 individuals hired by Pulmonx in the first two quarters of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.

Jun 01, 2026 12:05 PM • globenewswire.com

Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

May 12, 2026 09:10 AM • seekingalpha.com

Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript

Apr 29, 2026 09:21 PM • seekingalpha.com

Pulmonx price target lowered to $4 from $8 at Lake Street

$4.00 (was $2.42)

Lake Street

Oct 28, 2025 08:42 AM • TheFly

Pulmonx downgraded to Neutral from Overweight at Piper Sandler

$2.50 (was $3.15)

Jason Bednar · Piper Sandler

Jul 31, 2025 05:05 AM • TheFly

Pulmonx price target lowered to $10 from $12 at Piper Sandler

$10.00 (was $6.79)

Jason Bednar · Piper Sandler

Oct 31, 2024 03:39 AM • TheFly

Pulmonx price target raised to $16 from $15 at Canaccord

$16.00 (was $7.42)

William Plovanic · Canaccord Genuity

Aug 01, 2024 04:39 AM • TheFly

Lake Street Capital Markets Starts Pulmonx Corp. (LUNG) at Buy

$12.00 (was $7.00)

Frank Takkinen · Loop Capital Markets

Jun 04, 2024 04:11 AM • StreetInsider

Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $9.5

$9.50 (was $7.88)

Morgan Stanley

Jan 06, 2023 05:15 AM • Benzinga

Wells Fargo Maintains Equal-Weight on Pulmonx, Lowers Price Target to $6

$6.00 (was $6.22)

Wells Fargo

Dec 12, 2022 05:17 AM • Benzinga

Citigroup Upgrades Pulmonx to Buy, Lowers Price Target to $10

$10.00 (was $5.88)

Citigroup

Dec 12, 2022 02:34 AM • Benzinga

Stifel Maintains Buy on Pulmonx, Lowers Price Target to $20

$20.00 (was $16.37)

Stifel Nicolaus

Jul 18, 2022 05:44 AM • Benzinga

Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $19

$19.00 (was $16.20)

Morgan Stanley

Jul 15, 2022 08:03 AM • Benzinga